People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

The Pharmaceuticals division grew revenues by ~4%, to ~$50.3bn, while the diagnostics division's revenues fell by ~1% ... to semaglutide, tirzepatide, and a host of other clinical stage GLP ...

Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1 RA/gastric inhibitory polypeptide (GIP) medication tirzepatide, have gained ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Just over ...

"It is estimated that by 2030, 30 million GLP-1 ... 4 (range 37-77), and 56% were women. All patients were initially seen in a community setting. Of the seven with NAION, four were taking ...

Two examples of GLP-1 medications currently on the market include semaglutide and tirzepatide. Semaglutide, also known by the brand name Ozempic, first saw widespread use after trial data showed ...

With the FDA's approval, the medicine, chemically known as semaglutide, will become the first GLP-1 treatment option for persons with type 2 diabetes and chronic kidney disease. “Such an ...